Ascendis Pharma A (ASND) Cost of Revenue (2021 - 2026)

Ascendis Pharma A has disclosed Cost of Revenue across 6 years of filings, most recently posting $20.5 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $20.5 million, up 11.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $109.7 million (up 88.96% YoY), and the FY2025 annual result was $136.2 million, up 178.41% from the prior year.
• Cost of Revenue came in at $20.5 million for Q1 2026 at Ascendis Pharma A, down from $27.5 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $35.6 million in Q2 2025 to a low of $1.2 million in Q2 2022.
• The 5-year median for Cost of Revenue is $12.3 million (2024), against an average of $13.9 million.
• Across the five-year window, Cost of Revenue soared 1114.91% in 2023 and declined 28.42% in 2024, its largest moves.
• Ascendis Pharma A's Cost of Revenue stood at $5.2 million in 2022, then surged by 301.47% to $20.9 million in 2023, then slipped by 28.42% to $15.0 million in 2024, then jumped by 83.31% to $27.5 million in 2025, then dropped by 25.35% to $20.5 million in 2026.
• The last three Cost of Revenue figures came in at $20.5 million (Q1 2026), $27.5 million (Q4 2025), and $26.1 million (Q3 2025), per Business Quant data.